Serum HCV-RNA levels in patients with chronic hepatitis C: Correlation with histological features

Al-Khurri, Luay E.; Al-Khafaji, Khitam R.; Al-Salihi, Suhair A.; Alwaysi, Safa Abdulkareem; Al-Akayshi, Raghad J.

doi:10.1016/j.ajg.2009.03.003

Cited by 7 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the results of this study, FibroScan measurements did not significantly correlate with AST/ALT, indicating that this ratio is not a good and discriminative index for estimating fibrosis extent in chronic HCV infection as previously demonstrated by others (30,31). Al-Khurri et al in their study concluded that serum HCV RNA level does not determine the development of liver damage and fibrosis (32). This is in line with the results of this study and suggests that HCV RNA titers and liver injury markers are not effective in the diagnosis of the degree of liver fibrosis in chronic HCV positive patients.…”

Section: Discussionsupporting

confidence: 88%

Relationship between Duffy Antigen Receptor for Chemokines and Clinical Characteristics in Han People with Chronic Hepatitis C Infection in Dalian, China

Shao¹,

Zhou²,

Liu

2020

ircmj

View full text Add to dashboard Cite

Background and Objectives: Most patients with untreated chronic hepatitis C virus (HCV) infection develop hepatic fibrosis. Hepatic disease progression is monitored with hematological markers (alanine aminotransferase [ALT], aspartate aminotransferase [AST], albumin and platelet [PLT] count, AST/ALT ratio, AST/PLT ratio index [APRI], and fibrosis 4 score [FIB-4]) and FibroScan. The present study aimed to investigate the association between Duffy antigen/chemokines receptor (DARC) polymorphisms and clinical parameters in the Han people with chronic hepatitis C infection in Dalian, China. Materials and Methods: This cohort study was performed on 245 Han people with chronic HCV at Dalian infectious hospital during April-December 2015. The participants of the research were selected using the consecutive sampling method. The DARC genotyping was performed using the TaqMan probe method and transient elastography was measured by FibroScan. Results: Based on the findings, DARC polymorphisms correlated with ALT concentrations (FY*A/FY*A vs. FY*A/FY*B, P=0.025). However, the DARC polymorphism did not have an association with HCV RNA titers (FY*A/FY*A vs. FY*A/FY*B, P=0.241) or hepatic fibrosis (FY*A/FY*A vs. FY*A/FY*B, P=0.325). Moreover, correlation analyses showed that APRI (P<0.001, rho=0.603) and FIB-4 (P<0.001, rho=0.698) were useful predictors of hepatic fibrosis in chronic HCV infection. Besides, HCV RNA titers (P=0.327) and hepatic injury markers (P=0.814, 0.198, 0.767, and 0.171 for ALT, AST, ALB, and AST/ALT, respectively) were not useful for the estimation of the fibrosis stage in patients with chronic hepatitis C. Conclusion: The FY*A allele is a potentially valuable protective factor against hepatocyte damage in chronic HCV-infected patients.

show abstract

Section: Discussionsupporting

confidence: 88%

Relationship between Duffy Antigen Receptor for Chemokines and Clinical Characteristics in Han People with Chronic Hepatitis C Infection in Dalian, China

Shao¹,

Zhou²,

Liu

2020

ircmj

View full text Add to dashboard Cite

show abstract

“…The correlation among HCV genotypes with viral load and serum markers and their association with disease severity and sensitivity to interferon treatment remains controversial till date [ 26 , 27 ]. Evaluating the correlation between different clinical markers with genotypes, our results showed that a combination of four clinical markers (ALT, AST, ALP and bilirubin level) and serum viral load can have high positive or negative predictive value for diagnosis of different HCV genotypes.…”

Section: Discussionmentioning

confidence: 99%

HCV genotype-specific correlation with serum markers: Higher predictability for genotype 4a

Ahmad

Ijaz

Javed

et al. 2011

Virol J

View full text Add to dashboard Cite

BackgroundSeveral factors have been proposed to assess the clinical outcome of HCV infection. The correlation of HCV genotypes to possible serum markers in clinical prediction is still controversial. The main objective of this study was to determine the existence of any correlation between HCV genotypes to viral load and different clinical serum markers.MethodsWe performed a prospective cross-sectional and observational study. About 3160 serum HCV RNA positive patients were chosen from 4020 randomly selected anti-HCV positive patients. Statistical analysis was performed using the SPSS 16 software package. ROC (receiver operating characteristics) curves were used to compare diagnostic values of serum markers to predict genotypes.ResultsThe most prevalent genotype was 3a (73.9%) followed by 1a (10.7%), 4a (6.4%) and 3b (6.1%) in Pakistani population. No correlation was found between viral load and serum markers for genotype 3a in a large no. of sample (n = 2336). While significant correlation was observed between viral load and AST in genotype 3b, ALP with viral load and ALT for genotype 1a. Patients with genotype 4a showed a significant inverse correlation with viral load and Hb level and AST with ALP. For genotype 4a, AUC (area under the curve) of ALT, ALP, AST, bilirubin, Hb level and viral load was 0.790, 0.763, 0.454, 0.664, 0.458 and 0.872 respectively.ConclusionsIn conclusion, there was a significant variable response of HCV genotypes with serum markers. Severity of disease is independent of serum marker level in genotype 3a, while the liver damage in genotype 4a may associate with viral cytopathic effect as well as the immune-mediated process. An index using six serum markers may correctly predict genotype 4a in patients with ≥75% accuracy.

show abstract

“…In the literature studies have demonstrated different relations among degrees of fibrosis and viral load. Although Vieira 21 affirmed a significant correlation between advanced fibrosis and high HCV-RNA indices in the treatment outcome, other studies did not find this correlation 22,23 .…”

Section: Discussionmentioning

confidence: 92%

Treatment of chronic Hepatitis C with daclatasvir, sofosbuvir and simeprevir in patients from the reference hospital of infectology in central Brazil/ Tratamento da Hepatite C crônica com daclatasvir, sofosbuvir e simeprevir em pacientes do hospital de referência de infectologia do centro do Brasil

Gonçalves¹,

Sirqueira²,

Aires³

et al. 2021

BJDV

View full text Add to dashboard Cite

The drug treatment of hepatitis C represents a great therapeutic advance in favor of the elimination of the virus. The present study assessed the efficacy of treatment regimens involving direct action antivirals (DAAs), given to patients with chronic hepatitis C, attended at a referral hospital of infectology, central Brazil. This is a descriptive and cross - sectional study, based on the electronic database of the outpatient pharmacy, that evaluated the characteristics of patients and drug regimens involving DAA, from November 2015 to June 2017. Among 717 patients enrolled in this study, most of them had advanced liver fibrosis, were treatment naïve and HCV genotype 1 infected almost 80% of participants. A high efficacy of HCV treatment was achieved with 97% (95% CI: 94.9-98.2%) of SVR among the 431 patients who presented the results of viral load tests (HCV-RNA) at 12 weeks post-treatment. Patients infected with genotype 3 and who were cirrhotic had a lower SVR rate (87%). Treatment efficacy was not associated with age or sex among participants. The results of this study corroborate the findings in literature that showed a high efficacy of DAAs in the treatment of chronic hepatitis C, implemented through the clinical protocol and therapeutic guidelines for hepatitis C of the Ministry of Health in 2015. Many challenges must be overcome in order to combating viral hepatitis. In this context, the efficacy of HCV treatment it is an important issue to achieve the HCV elimination as a public health threat

show abstract

Serum HCV-RNA levels in patients with chronic hepatitis C: Correlation with histological features

Cited by 7 publications

References 30 publications

Relationship between Duffy Antigen Receptor for Chemokines and Clinical Characteristics in Han People with Chronic Hepatitis C Infection in Dalian, China

Relationship between Duffy Antigen Receptor for Chemokines and Clinical Characteristics in Han People with Chronic Hepatitis C Infection in Dalian, China

HCV genotype-specific correlation with serum markers: Higher predictability for genotype 4a

Contact Info

Product

Resources

About